SMA Research Platform

Evidence graph for Spinal Muscular Atrophy

Biology-first target discovery
Christian Fischer / Bryzant Labs
15,945Targets
453Trials
85Drugs
7Datasets
8,004Sources
221,721Claims
232,882Evidence
73,172Hypotheses
DRUGphase2small molecule

Ignaseclant

Brand names: NMD670

Mechanism

ClC-1 (CLCN1) skeletal-muscle chloride channel inhibitor — improves muscle function as an adjunct to SMN-restoring therapy

Related claims (0)

No claims matched “Ignaseclant” in free-text search.

Off-Target Findings (0)

No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.

Login → Command Center